TP53 and myeloproliferative neoplasm: TARGET-seq uniquely enabled phenotypic and molecular characterization of rare TP53-WT cells, referred to as pre-LSCs, which include both residual HSPCs that were WT for all mutations analyzed, as well as HSPCs that form part of the antecedent MPN clone.